Next-generation Medtech innovator Kurve Therapeutics begins
an equity crowdfunding journey with its $50 million Regulation A+ raise.
Private investors can now invest in a company aiming to
disrupt and transform a $1.3 trillion dementia market alone while benefiting
millions living with neurodegenerative diseases.
Caption: Transformative Dementia and Alzheimer’s treatment company
Kurve Therapeutics launches $50 million equity crowdfunding raise
Diseases like Dementia and Alzheimer's afflict millions of
people across the globe, while over 1 billion people worldwide – 1 in 6 –
suffer from a neurological disease. Yet, Healthcare sectors lack effective,
Kurve Therapeutic's patented intranasal drug delivery
technology, Controlled Particle Dispersion® (CPD), has been shown to bypass the
blood-brain barrier, delivering 30x more medication directly to the brain than
Marc Giroux, Kurve Therapeutics CEO and founder said:
"An IV infusion manages to deliver one-tenth of 1% through the blood-brain
barrier. We have measured our success at 30 times more than that. This is not
an insignificant achievement.
"Central nervous system disorders are a scourge because
they are challenging to treat by their very nature. We have the potential to
eliminate this problem, so an unmet need becomes a met need,"
Giroux now hopes to blast Kurve Therapeutics into a new
growth period, teaming up with award-winning broker-dealer Rialto Markets'
crowdfunding infrastructure and technology for its Regulation A+ offering:
"Following extensive work developing treatments and our
CPD technology, we are ready to scale the company and grow our investor
"We plan to invest most of our proceeds into our final
phase III clinical trials for intranasal insulin for mild cognitive impairment
in Alzheimer’s. Kurve Therapeutics is ready for Phase III clinical trials in
three separate disease states and is one Phase III study away from being
eligible for FDA approval."
Caption: Rialto Markets CEO & Co-Founder Shari
Rialto Markets CEO and Co-founder Shari Noonan said:
"Kurve Therapeutics' intranasal drug delivery technology has the potential
to transform the lives of millions suffering from neurodegenerative diseases.
"This is a very exciting and important sector which
needs this essential innovation, so we are delighted that Kurve Therapeutics
chose to work with us to grow and scale."
Rialto Markets' has a capital raising infrastructure for Reg
CF and Reg A+ equity crowdfunding as well as Reg D institutional investment
offering. Alongside this, Rialto Markets has a pioneering secondary market
alternative trading system (ATS) which empowers the buying and selling of
shares in private companies or other private securities, which can operate
similarly in a regulated framework and environment as a stock exchange does
such as the Nasdaq and NYSE for public company trading.
This secondary trading ATS allows private companies and
shareholders to potentially create liquidity and trading within a $7
trillion-dollar private securities market set to grow to $30 trillion by 2030,
potentially enabling greater access to vital funding and private securities
within a fully regulated environment.